| Name | Title | Contact Details |
|---|
Microbion is a clinical stage biopharmaceutical company. Microbion is developing MBN-101 as the first product in the bismuth-thiol class for the treatment of resistant and difficult to treat infections. MBN-101 has broad spectrum, anti-bacterial efficacy against a broad range of pathogens, including multiple priority pathogens or “superbugs”. In addition to anti-bacterial efficacy, MBN-101 also has highly advantageous and product-differentiating capability to prevent and eradicate microbial biofilms. The dual action from this first in class product provides a novel clinical approach to treating infections. Their effectiveness against MRSA, MDR TB, CRE, VRE, and other antibiotic resistant pathogens highlights their potential to provide solutions to the dramatic and alarming increase in global antibiotic resistance.
Centrillion Biosciences is a leading genomic and bioinformatics solution provider.
At VAYA Pharma, we are committed to improving quality of life and delivering products that exemplify our key values. VAYA Pharma`s history of clinical research is based on understanding the potential of the human body in order to reform medicine. Through this research, we have discovered a strong correlation between certain disorders and lipid imbalances in affected individuals. Because of this, VAYA Pharma focuses on developing innovations for the clinical dietary management of disorders that are specifically associated with lipid imbalances. Our products deliver a nutritional based solution that are familiar to the human body and clinically proven to be safe and effective with virtually no side effects. Using lipid-based ingredients, our innovative products address nutritional needs of people with health conditions that cannot be met through modification of diet alone.
Dzeel Clinical is a Garner, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2004, Rapid Pathogen Screening is an emerging developer, manufacturer, and marketer of rapid point-of-care (POC) diagnostic tests. The company’s innovative and patented technology platform facilitates the development of a spectrum of cost-effective tests to rapidly identify patients with infectious diseases and inflammatory conditions. As a result of U.S. government contracts, this platform is also being used to develop tests for bio-terrorism and chemical nerve agent blood toxins. RPS tests have high sensitivity and specificity, and can be easily performed by a clinician or their staff without extensive training or additional equipment.